Literature DB >> 20801000

Leishmaniasis vaccines: past, present and future.

Farrokh Modabber1.   

Abstract

No vaccine exists against any form of leishmaniasis. Because recovery from infection is usually accompanied by a strong immunity and because it is possible to protect experimental animals against live challenge, hope for the development of a vaccine for humans has been high. However, leishmaniasis is a disease of the poor and the market for a vaccine is very limited. Until a few years ago, with minimal resources, only a pragmatic approach was possible for testing the first-generation vaccines (i.e. killed whole parasites). Recently, funding has become available for developing defined second-generation vaccines, including recombinant proteins and DNA constructs. With new adjuvants also being developed there is new hope, and several new vaccines are in development against leishmaniasis.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801000     DOI: 10.1016/j.ijantimicag.2010.06.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  21 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 2.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

3.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

4.  Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Authors:  Carmel B Stober; Selma M B Jeronimo; Nubia N Pontes; E Nancy Miller; Jenefer M Blackwell
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

5.  Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7-dibromocryptolepine against Leishmania donovani promastigotes.

Authors:  Sudipta Hazra; Subhalakshmi Ghosh; Sukalyani Debnath; Scott Seville; Vijay Kumar Prajapati; Colin W Wright; Shyam Sundar; Banasri Hazra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

6.  CCR7+ central and CCR7- effector memory CD4+ T cells in human cutaneous leishmaniasis.

Authors:  Hossein Keshavarz Valian; Mahmoud Nateghi Rostami; Minoo Tasbihi; Akram Miramin Mohammadi; Seyed Ebrahim Eskandari; Abdolfattah Sarrafnejad; Ali Khamesipour
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

7.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

8.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

9.  Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Fatemeh Doustdari; Azam Bolhassani; Delaram Doroud; Hiva Azizi; Kazem Heidari; Mohammad Vasei; Nabiollah Namvar Asl; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18

10.  Spatial distribution and molecular identification of leishmania species from endemic foci of South-eastern iran.

Authors:  F Sharifi; I Sharifi; M Zarean; M Hakimi Parizi; Mr Aflatoonian; M Fasihi Harandi; R Zahmatkesh; M Mashayekhi; Ar Kermanizadeh
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.